• $45 million investment delivers critical domestic sterile manufacturing capacity to pharmaceutical partners
• Dozens attend open house prior to GMP qualification process to get a sneak peek at the new sterile injectable line

Whippany, NJ – August 20, 2026 – Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, is entering the final operational stages to activate its new sterile injectable manufacturing line. This milestone follows a $45 million facility investment designed to address the growing demand from US-based pharmaceutical companies that are seeking reliable domestic sterile manufacturing partners.

“The domestic supply chain for injectables is at capacity, and this is the exact right time to bring this investment online,” said Lee Karras, CEO of Halo Pharma. “This state-of-the-art asset introduces the advanced capabilities and high standards that both emerging biotech and large pharma companies expect from a premium CDMO partner.”

Purpose-built to support sterile injectable manufacturing from clinical development through commercial production, Halo Pharma’s new platform features a high-speed Groninger UFVN FlexFill syringe, cartridge, and vial filling line, along with an integrated SKAN isolator to enhance production efficiency and support EU Annex 1 compliance. Once online, the platform will allow Halo Pharma to manufacture batch sizes ranging from 250-250,000 units with annual capacity to produce more than 50 million units, based on 1 ml syringes and 250L batches. This expands on the oral solid dose, semi-solid, and liquid formulation development the company has offered customers for more than 20 years.

Halo Pharma hosted customers and industry colleagues to give them a preview of their new capabilities, and the company is now proceeding through the Good Manufacturing Practice (GMP) qualification process. It is expected to be brought online later this year.

For more information about Halo Pharma, visit https://halopharma.com.

About Halo Pharma
Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise, as well as a wide spectrum of manufacturing services, from its locations in Whippany, New Jersey, USA, and Montreal, Quebec, Canada, to its international client base. Halo Pharma offers fully integrated capabilities across a variety of dosage forms, including solid, semi-solid, and oral liquid, and is expanding to include sterile vial, prefilled syringe, and cartridge formats. The company is registered to work with any of these dosages in the CI–CV DEA designations. Halo Pharma’s capabilities in tech transfer, process and product development, production, scale-up/validation, and analytical method development allow it to partner with clients from development through commercialization—or at any point along the way. For more information, please contact services@halopharma.com.

Media Contact
Resource Advantage
Dan Green
dgreen@resourceadvantage.com

Company Contact
Halo Pharma
Stacy London
Stacy.london@wssterile.com